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ScienceDirectThe rising prevalence of antibiotic resistant bacteria is an
increasingly serious public health challenge. To address this
problem, recent work ranging from clinical studies to
theoretical modeling has provided valuable insights into the
mechanisms of resistance, its emergence and spread, and
ways to counteract it. A deeper understanding of the underlying
dynamics of resistance evolution will require a combination of
experimental and theoretical expertise from different
disciplines and new technology for studying evolution in the
laboratory. Here, we review recent advances in the quantitative
understanding of the mechanisms and evolution of antibiotic
resistance. We focus on key theoretical concepts and new
technology that enables well-controlled experiments. We
further highlight key challenges that can be met in the near
future to ultimately develop effective strategies for combating
resistance.
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Introduction
Progress in our quantitative understanding of the evolu-
tionary dynamics leading to antibiotic resistance holds
promise to help avert the looming resistance crisis [1].
While changes in antibiotic prescription strategies can
contribute to countering resistance [2], optimized treat-
ment schemes that take into account the dynamics of
resistance evolution are urgently needed. The best-
known mechanisms of antibiotic resistance commonly
found in the clinic or laboratory include antibiotic degrad-
ing enzymes, drug target modification, efflux, and the
prevention of drug uptake [3–6]. These mechanisms have
been characterized in great detail in decades of fruitful
work, culminating in databases of the ‘resistome’—the
collection of all known genes conferring resistance [7–9].Current Opinion in Biotechnology 2017, 46:90–97 More recently, transcriptomic studies have provided a
useful intermediate phenotypic description of resistance,
showing that information on global gene expression can
improve predictions of the resistance phenotype com-
pared to genotypic data alone [10,11].
The resistance of a bacterium to a drug is determined by
measuring the minimal inhibitory concentration (MIC),
that is, the lowest concentration that completely inhibits
growth of a clonal culture [12]. An increase in resistance
occurs when the population can grow in higher concen-
trations of antibiotic. Resistance is a genetically inherited
trait, acquired by bacteria through one of two main
processes: spontaneous de novo mutations and horizontal
gene transfer [13,14]. Still, the level of resistance is often
not entirely determined genetically, but can be hetero-
geneous within a population, depend on the environ-
ment, on the population structure, or on the physiological
state of the cell [15–18]. In this review, we focus on
specific examples where population dynamics and cell
physiology affect drug sensitivity, and on quantitative
aspects that determine the emergence and spread of de
novo resistance mutations. We particularly emphasize
recent studies that combined experiments and theoretical
modeling. Related influential studies on collective resis-
tance and on the effect of drug combinations on resistance
evolution have been reviewed elsewhere [19–23].
Role of cell physiology and population
effects in resistance
The growth rate of a bacterium depends on the nutrient
environment and is a key physiological parameter that can
strongly affect its sensitivity to a wide range of antibiotics
[15,24,25,26]. A recent experimental-theoretical study
focused on ribosome-binding antibiotics, and showed that
a lower growth rate (achieved by different growth media)
increases the tolerated antibiotic concentration while for
others, the opposite effect occurs [24]. A mathematical
model based on bacterial ‘growth laws’ [27], which take
into account how the ribosome concentration in the cell
depends on growth rate, showed that the ribosome-bind-
ing kinetics of the drug can explain this effect: slow-
growing cells are more resistant to reversibly binding
drugs, whereas fast-growing cells are more resistant to
irreversibly binding drugs [24]. These results would
have been hard to intuit without using a rigorous theo-
retical approach and highlight that apart from specific
molecular mechanisms, global cell physiology and growth
rate are important determinants of antibiotic resistance
levels.www.sciencedirect.com
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Glossary
MIC: Minimal inhibitory concentration. The lowest concentration of
an antibiotic that completely inhibits growth of a clonal culture.
TEM-1 b-lactamase: An enzyme produced by bacteria that cleaves
and deactivates b-lactam antibiotics.
DFE: Distribution of fitness effects. The probability distribution that
represents the changes in fitness caused by single-step mutations
originating from a common genotype. It depends on the ancestral
genotype and on the environment.
Epistasis: The phenomenon that the effect of a mutation depends on
the genetic background it occurs in.
Discrete fitness landscape: A graph in which the vertices are
genotypes, each with an assigned fitness value. Two genotypes are
connected by an edge if they are a single mutational event apart.Global cell physiology can even explain how a clonal
population diversifies into growing and non-growing cells
in the presence of antibiotics. The expression of many
genes increases with increasing growth rate [28]; this
effect alone can lead to bistable population dynamics
[29]. Specifically, it was shown that in an Escherichia coli
strain that expresses the cat1 enzyme, which inactivates
the antibiotic chloramphenicol (Table 1), a positive feed-
back loop occurs where a decrease in growth rate due to
addition of more chloramphenicol decreases expression of
the resistance-conferring enzyme, thus slowing growth
even further [30]. Theory shows that such a positive
feedback loop can lead to bistability, that is, coexistence
of growing and non-growing cells at the same drug con-
centration; this striking effect was confirmed in single cell
experiments [30]. Growth bistability is likely a more
general phenomenon [31] that occurs for other resistance
mechanisms and highlights that the response of a popu-
lation of clonal bacteria to antibiotics is not simply given
by many identical copies of the same cell.
Population effects are also important when resistance is
due to extracellular antibiotic degradation. Here, the
antibiotic concentration in the medium strongly depends
on the cell density, since higher densities lead to faster
antibiotic degradation. The inoculum size of the culture
thus affects the growth of all cells and, ultimately, the
measured resistance level. This effect has been described
in mathematical models and experimentally validated
using the beta-lactamase enzyme which degrades beta-
lactam antibiotics (including amoxicillin, ampicillin, and
cefotaxime) [32,33]. Such effects generally occur when-
ever a resistant subpopulation degrades or modifies theTable 1
Glossary of antibiotics and their targets
Antibiotic Target
Chloramphenicol 50S ribosomal subunit
Tetracycline 30S ribosomal subunit
Amoxicillin Cell wall synthesis
Trimethoprim Folate synthesis (DHFR)
Ciprofloxacin DNA replication (DNA gyrase)
www.sciencedirect.com antibiotic so that the entire population can benefit from it.
It will be interesting to further investigate the causes and
consequences of these effects which also occur for other
antibiotics [34].
Studying antibiotic resistance using
experimental evolution
Beyond characterizing existing resistance mechanisms, it
is a fundamental question how de novo resistance evolves.
Understanding this can ultimately lead to strategies for
inhibiting resistance evolution. Recent years have seen a
plethora of novel techniques for investigating antibiotic
resistance evolution in the laboratory and for systemati-
cally addressing its reproducibility, speed, molecular ori-
gins, and constraints.
Resistance often evolves so fast that it can be studied in
the laboratory but it is still challenging to obtain quanti-
tative and reproducible results. Serial transfer of microbial
cultures is a common experimental evolution protocol
[35] that is also useful for studying resistance evolution
[22,36,37]. In this protocol, bacterial cultures grow in
flasks or on microtiter plates and are diluted into fresh
medium by a fixed factor at regular time intervals (e.g.,
every 24 hours). These experiments can be continued
virtually indefinitely: Richard Lenski’s seminal long-term
evolution experiment [35] has exceeded a staggering
60 thousand generations in 28 years and is still ongoing.
Because of the relative simplicity of this protocol, it is
feasible to run hundreds of evolution experiments in
parallel. Together with increasingly inexpensive whole
genome sequencing techniques [38], this opens the door
for a statistical investigation of the intrinsically stochastic
evolutionary dynamics and for identifying general prin-
ciples governing microbial evolution [39–42]. A drawback
of serial transfer protocols is their inability to keep key
parameters that affect the evolutionary process well-con-
trolled: the population size fluctuates considerably and
cultures differ in their growth rates and in the time they
spend in stationary phase. This complicates the quanti-
tative investigation of the evolutionary process and its
comparison among different cultures. Furthermore, it is
not straightforward how the antibiotic concentration
should be chosen in such experiments to gain maximum
insight into the process of resistance evolution: if it is too
low, there is virtually no selection for resistance; if it is too
high, cells cannot grow at all, preventing them from
evolving at a significant rate.
Recently developed techniques in which bacteria are
exposed to increasing antibiotic concentrations solve this
problem. Theoretical work suggested that temporal or
spatial selection gradients can facilitate the sequential
emergence and fixation of multiple resistance mutations
leading to increasingly higher resistance levels [43,44].
Consequently, advanced protocols that gradually increase
antibiotic concentrations in time or space have beenCurrent Opinion in Biotechnology 2017, 46:90–97
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‘morbidostat’: this feedback-controlled device keeps cul-
tures growing in exponential phase and automatically
increases the antibiotic concentration during the experi-
ment such that they keep growing at a pre-defined rate
despite their increasing resistance. In this way, strong
selection pressure for resistance is constantly maintained.
For some antibiotics, this protocol enabled the highly
reproducible evolution of a 1000-fold resistance
increase in just a few weeks [47].
Spatial antibiotic gradients may enable even faster resis-
tance evolution. A striking example is given by a recently
developed microfluidics device: a concentration gradient
of the fluoroquinolone antibiotic ciprofloxacin (Table 1)
was maintained across this 2–3 cm hexagonal device
that consists of over 100 micro-compartments that are
connected, allowing cells to move between different
concentrations. From an initial population size of 106
cells, the authors observed a surprisingly strong, over
200-fold resistance increase that resulted from multiple
reproducible mutations that had occurred as early
as 10 hours after inoculation [48]. A recent study sizedFigure 1
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Current Opinion in Biotechnology 2017, 46:90–97 the assay oppositely and followed evolution on a huge,
meter-scale agar plate (the ‘MEGA plate’) [45]. In
contrast to small agar plates where rapid diffusion quickly
destroys spatial drug concentration gradients, they remain
relatively stable on this larger plate. Further, the size of
the plate allows for large bacterial population sizes that
should accelerate the occurrence of resistance mutations.
Fast resistance evolution reaching extremely high levels
within weeks was observed for different antibiotics.
Changing the slope of the concentration gradient
revealed that smaller steps in drug resistance enable
the multi-step evolution of high resistance levels that
are practically impossible to reach in a single mutation
step [45]. A fascinating aspect of this experiment is that
the front of bacteria that grows across the plate can be
viewed as a living Muller diagram that directly visualizes
the evolutionary record and the key role of stochastic
events in this process (Figure 1a,b): some of the most
highly resistant lineages ultimately stalled in this assay
because they emerged in an unfavorable location too far
away from the growth front [45], illustrating the sto-
chasticity of the process. Together, these results highlight
the great potential of new assays with well-defined spatial(C)
Current Opinion in Biotechnology
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evolution.
Apart from experiments where the antibiotic concentra-
tion increases monotonously, evolution has been studied
under different temporal sequences of antibiotic expo-
sure. In a recent experiment, E. coli cultures were repeat-
edly exposed to a high concentration of ampicillin for a
fixed time, followed by complete removal of the drug and
growth in its absence. In this assay, the bacteria did not
evolve resistance at all but instead genetically tuned their
lag times to match the duration of the antibiotic exposure
[49]—a stunning observation and an effective survival
strategy as the antibiotic used can only kill growing cells.
The effect of various temporal exposure protocols on
resistance dynamics was also studied at the single-cell
level. A recent study used a synthetic stochastic switch
controlling tetracycline resistance and observed the effect
of antibiotic pulse length on the probability of selective
sweeps in a microfluidic device; an intermediate regime
in which sweeps are unlikely was identified [50]. Overall,
these studies provide powerful tools for observing resis-
tance evolution at different levels; however, mathemati-
cal models are needed to interpret the data and extrapo-
late to predictions beyond the laboratory.
Quantitative understanding of resistance
mutations and their genetic interactions
The key ingredients entering theoretical descriptions
of evolution are mutation and selection. While mutation
rates can be estimated [51], the fate of mutations in the
face of selection is determined by their effects on survival
and growth (fitness) of the organism in the current envi-
ronment. In theory, the probability that a new mutation
has a certain fitness effect is determined by the so-called
distribution of fitness effects (DFE) [52]. In practice,
the shape of this distribution is hard to measure and
has remained elusive. Approximations of the DFE for
specific environments can be obtained by direct compe-
tition with the ancestor [42,53], or by comparing growth
rates [54] or survival in high drug doses [55] for a large
number of mutants. The shape of the DFE is crucial for
the evolutionary dynamics. For example, it is a classical
result that, for two DFEs with the same mean fitness
effect but different variances, the one with the greater
variance provides a greater probability for the occurrence
of highly beneficial mutations and thus speeds up evo-
lution. Recent studies have measured DFEs relevant for
the specific case of antibiotic resistance evolution and
revealed general relations that partly explain the shape of
this distribution [46–48].
The width of the DFE in the presence of antibiotics was
shown to depend strongly on the dose–response charac-
teristics of the drug. The DFEs for eight antibiotics
spanning diverse modes of action were approximated
by measuring the growth rates under those antibioticswww.sciencedirect.com for all 4000 strains of the E. coli gene deletion library
[54,56]. Interestingly, the widths of the distributions
vary drastically across antibiotics. These differences are
largely explained by the shape of their dose response
curves: when the growth rate is sensitive to small differ-
ences in the concentration of a particular antibiotic, the
corresponding DFE is wide. Conversely, for antibiotics
where the growth rate is robust to such small dose
differences, the corresponding DFE is narrow (Figure 2)
and can even become narrower than in the absence of
drug. A population genetics model predicted that the rate
of resistance evolution and the diversity of evolutionary
paths should increase for antibiotics with greater DFE
width when compared to antibiotics with similar dose–
response characteristics. These predictions were con-
firmed in evolution experiments using the morbidostat
[54]. These results highlight the potential of identifying
key factors that determine the shape of the DFE for
different antibiotics and bacteria; identifying such factors
can enable increasingly accurate predictions of resistance
evolution.
DFEs of mutations restricted to specific resistance genes
can be measured more comprehensively and have
revealed surprising features. A notable example is the
DFE of the TEM-1 b-lactamase that was tackled in
several recent efforts. First, beneficial mutations were
detected by screening a randomly mutagenized library for
TEM-1 variants that convey resistance to cefotaxime, and
their resistance levels were quantified [57]. Second, the
amoxicillin MIC was measured for 64% of all possible
amino-acid substitutions in the TEM-1 enzyme; their
effects were partially explained by amino acid properties
and calculated protein stability changes [55]. Both studies
consistently found that a few mutations have a much
greater effect on fitness than predicted from an often
assumed exponential DFE. This result suggests that
evolution may be more predictable than expected—at
least for resistance enzymes. Finally, a high-resolution
map of the fitness effects for over 98% of all possible point
mutations in the TEM-1 gene was assembled; this map
suggested that the genetic code biases mutations toward
beneficial effects [58]. The TEM-1 b-lactamase became a
model system for the detailed understanding of DFEs in
the context of antibiotic resistance; results from this
system suggest that amino-acid properties and protein
stability can help to predict the effects of many mutations.
The DFE generally depends on the genetic background;
it can thus change as soon as the first mutation has
occurred. The phenomenon where the effect of muta-
tions depends on the presence of other mutations is
termed ‘epistasis’ [59]. Measuring the extent of epistasis
is important for evolutionary predictions because preva-
lent epistasis often leads to multiple fitness peaks and can
prevent a population from reaching the global fitness
maximum [60]; in particular, this is the case forCurrent Opinion in Biotechnology 2017, 46:90–97
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Dose–response characteristics of antibiotics shape the distribution of fitness effects.
Schematics of two different dose response curves: the left curve is steep, that is, the growth rate is sensitive to small changes in drug
concentration; the right curve is shallow. Mutations cause shifts in the effective drug concentration a bacterium experiences; the typical magnitude
of these shifts is surprisingly similar for diverse antibiotics [54]. The distribution of effective drug concentrations resulting from many different
mutations is shown in gray. These mutations produce distributions of growth rates (fitness) that are wide for the steep dose–response curve (left)
and narrow for the shallow dose–response curve (right).‘reciprocal sign epistasis’ where the fitness effect of a
mutation changes from positive to negative, depending
on the background [61]. Epistasis can be analyzed using
discrete fitness landscapes which are a powerful metaphor
for assessing the constraints and predictability of muta-
tional paths in evolution experiments [62,63]. A discrete
fitness landscape is a graph in which the vertices are
genotypes, and two genotypes are connected by an edge
if they are a single mutational event apart. The landscape
is completed by assigning a fitness value to all genotypes
(Figure 1c). Paths on the landscape are accessible if they
represent sequences of genotypes with monotonically
increasing fitness, that is, all mutations along the path
are beneficial. If only few of the possible paths are
accessible, evolutionary trajectories become more con-
strained and predictable. Due to the astronomically large
number of possible genotypes, it is not feasible to mea-
sure the fitness effects of all mutations and their combi-
nations experimentally, even for short sequences. There-
fore, recent studies have focused on full landscape
reconstructions of just a few mutations relevant for drug
resistance [62,63,64] and proposed biophysical models to
predict epistatic interactions from protein structure and
function [65,66].
The enzyme dihydrofolate reductase (DHFR) has served
as a key model for describing higher-order epistasis and
biophysical constraints of fitness landscapes. DHFR is the
target of trimethoprim (Table 1) and can cause resistance
to this antibiotic via a few point mutations. A recent studyCurrent Opinion in Biotechnology 2017, 46:90–97 reconstructed a fitness landscape of seven known resis-
tance mutations in DHFR [62]. It showed that when the
possibility of the same locus mutating more than once is
taken into account, prevalent epistasis may increase the
accessibility of all peaks on a landscape, decreasing the
chance of being ‘trapped’ at a suboptimal fitness [62]. A
later study measured the effects of three resistance muta-
tions in DHFR and their combinations on enzyme effi-
ciency, stability, and ability to bind trimethoprim [66]. It
discovered a trade-off between affinity to trimethoprim,
enzyme efficiency, and stability which shapes the epi-
static interactions in the fitness landscape. Further, the
activity of protein chaperones strongly affected the shape
of the fitness landscape by changing the stability of the
enzyme [66]. Together, these results underline the
importance of genetic interactions both within the same
gene and across different cellular mechanisms for pre-
dicting evolution.
A broader investigation of interactions between drug
resistance and other cellular functions, including seem-
ingly unrelated ones, can uncover potentiators of resis-
tance evolution, that is, genes that accelerate this process
[67]. Notable examples are mechanisms that increase
genetic variability by increasing the mutation rate in
response to an antibiotic challenge (stress-induced muta-
genesis). In particular, this can happen by upregulation of
the mutation-inducing SOS response [68–70], induction
of mutagenic oxidative damage [71,72], or by regulated
DNA uptake from the environment [73]. Mechanismswww.sciencedirect.com
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for new drugs that could be combined with established
antibiotics to hamper spontaneous resistance evolution—
an idea that has triggered efforts to develop SOS response
inhibitors [68,74,75].
In addition to potentiation through changes in mutation
rate, it will be interesting to identify mutations in other
cellular functions that may increase the rate of resistance
evolution via epistatic interactions. A conceptually
related phenomenon occurred in Richard Lenski’s long
term evolution experiment where certain potentiating
mutations were required before the ability to metabolize
citrate could evolve [76,77]. At the heart of this phenom-
enon is a particular substitution with minor effects on
fitness that allows for a secondary mutation to become
beneficial. Similar genetic interactions between resis-
tance mutations and genetic background can occur
[78], suggesting that the evolvability of antibiotic resis-
tance can be strongly affected by the presence of muta-
tions in diverse cellular pathways. A systematic identifi-
cation of mutations that produce significant changes in
resistance development would greatly enhance our
understanding of the complex interplay between drug
resistance and other cellular functions. If the effect of
these mutations can be chemically mimicked, this
research could lead to the discovery of new adjuvants
to antibiotics that slow down resistance evolution.
Conclusions
Over the last decade, the field has made considerable
progress in understanding antibiotic resistance evolution,
at least in well-controlled laboratory settings. Bacterial
growth laws have helped to elucidate the interplay
between cell physiology, antibiotic action, and resistance
and made accurate quantitative predictions of surprising
antibiotic effects. The success of studies thus far [24,30]
holds promise that a quantitative characterization of
bacterial physiology will also lead to an improved under-
standing of resistance mechanisms for antibiotics with
other targets than the ribosome.
New technology for evolution experiments together with
improved mapping of mutational fitness effects and epi-
static interactions will soon allow us to statistically test
predictions for evolution in various simple and structured
environments. A key challenge is to scale recently devel-
oped, precisely controlled lab evolution protocols [47] to
higher throughput so that many antibiotics and various
strains can be tested in parallel at high replication. This
technology would enable a systematic investigation of
mutations and other perturbations that affect resistance
evolution. It would further provide a deeper understanding
of the general principles of resistance evolution and enable
predictions of the differences in the propensity for resis-
tance evolution among bacteria and antibiotics. Beyond
such well-controlled experiments, a great challenge is towww.sciencedirect.com develop technology enabling experiments that mimic
the physiological environment as it occurs in an infec-
tion. Apart from the host immune system and physical
properties of the host environment, the presence of other
microbes at the infection site can affect the success of
antibiotic treatments targeted at a single pathogen. In
the long run, it will be crucial to translate the advances
on antibiotic resistance evolution into specific interven-
tion strategies that are effective against pathogenic
bacteria in an infected host but, unlike current treat-
ments, keep resistance in check.
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